Skip to main content

Optimizing Frontline Immunotherapy
in Advanced Non-Small Cell Lung Cancer

  • Registration:
  • CME Information or Content Source:
    Physician: .75 AMA PRA Category 1 Credit(s)™
  • Expires:
    April 7, 2023

Course Description

This continuing medical education (CME) activity will provide highlights from 2 Live Grand Round Sessions, offering expert insights on key concepts in immunotherapy for advanced NSCLC. Core topics include the rationale for immunotherapy, the critical importance of guideline-driven biomarker testing in patient selection, and the most current data on checkpoint inhibitor monotherapies, combinations, and emerging regimens.

Learning Objectives

Completion of the course will help you:

  • Identify patients with advanced NSCLC eligible for frontline immunotherapy using biomarker test results
  • Apply efficacy and safety data on frontline immunotherapy when treating patients with advanced NSCLC

Target Audience

This activity is intended for oncology, pathology, and pulmonology clinicians (MD/DO/NP/PA) engaged in the care of patients with non-small cell lung cancer (NSCLC).